Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08ANZ
|
|||
| Drug Name |
Pembrolizumab
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Melanoma [ICD-11: 2C30; ICD-9: 172] | Approved | [1], [2] | |
| Breast cancer [ICD-11: 2C60-2C65] | Phase 3 | [3] | ||
| Colorectal cancer [ICD-11: 2B91.Z] | Phase 3 | [3] | ||
| Esophageal cancer [ICD-11: 2B70; ICD-9: 150] | Phase 3 | [3] | ||
| Hepatocellular carcinoma [ICD-11: 2C12.02; ICD-10: C22.0; ICD-9: 155] | Phase 3 | [3] | ||
| Renal cell carcinoma [ICD-11: 2C90; ICD-10: C64; ICD-9: 189] | Phase 3 | [3] | ||
| Small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162.9] | Phase 3 | [3] | ||
| Cutaneous squamous cell carcinoma [ICD-11: 2C30] | Phase 2 | [4] | ||
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 2 | [3] | ||
| Prostate cancer [ICD-11: 2C82.0; ICD-10: C61; ICD-9: 185] | Phase 2 | [3] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Phase 2 | [3] | ||
| Primary mediastinal B-cell lymphoma [ICD-11: 2A81; ICD-10: C83.3] | Application submitted | [3] | ||
| Company |
Merck Kenilworth, NJ
|
|||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Programmed cell death protein 1 (PD-1) | Target Info | . | [2] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| T cell receptor signaling pathway | ||||
| Reactome | PD-1 signaling | |||
| WikiPathways | T-Cell Receptor and Co-stimulatory Signaling | |||
| Costimulation by the CD28 family | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
| REF 2 | Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.